T he EMPA-REG OUTCOME (Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes trial) and CANVAS (Canagliflozin Cardiovascular Assessment Study) trials revealed that the antihyperglycemic sodium-glucose cotransporter 2 inhibitors (SGLT2i) empagliflozin and canagliflozin, developed to treat diabetes, confer a striking cardiovascular mortality benefit that cannot be attributed to glycemic control (1,2). Although these trials were not originated and designed to demonstrate primary benefit for heart failure, both trials revealed that these agents were associated with significant reduction in overall mortality, cardiovascular mortality, and heart failure hospitalization. These benefits did not appear to proceed through protection from myocardial ischemic insults (1,3). Moreover, a preclinical model of pressure overload-induced heart failure revealed that pathological ventricular remodeling was ameliorated by empagliflozin (4). However, the mechanisms underlying these benefits remain As a reflection of increased systemic fat oxidation, SGLT2i increases hepatic ketogenesis, even causing diabetic ketoacidosis at low incidence, but nonetheless high enough to modestly dissipate enthusiasm for their use. This concern has been countered by the notion that the benefit of SGLT2i may proceed in part by furnishing a greater supply of an alternative fuel, ketone bodies, to the failing heart. Indeed, rodent and human studies indicate that both the diabetic and the nondiabetic failing heart adapt by increasing ketone oxidation to offset metabolic abnormalities which restrict myocyte access to fatty acid and/or glucose substrate fuels (9-11). 
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[b-OHB]) oxidation was decreased in hearts from
db/db mice, and SGLT2i had no effect on this rate.
Overall, cardiac efficiency (work per unit of oxygen consumed) was not significantly improved by either empagliflozin or b-OHB.
In the absence of empagliflozin, the isolated working diabetic heart in these studies exhibited features of the classic "engine out of fuel," that is, low energy turnover and low cardiac output (12) . However, the ex vivo perfusion studies used only 5 mM glucose A key elusive question is the role of ketone bodies in the failing heart. Indeed, the pleiotropic effects of SGLT2i and whether myocardial ketone metabolism is necessary and sufficient to extend those benefits to myocardium still need to be carefully scrutinized.
Much evidence suggests the failing human heart relies on ketone oxidation to a greater extent. Circulating ketone concentrations are increased in nondiabetic patients with heart failure (13) . Studies in nonfailing human type 2 diabetes (11), nondiabetic human heart failure (10, 14) , and compensated pathological hypertrophy in mice (9) 
